Table I.
Information of 83 newly diagnosed patients with multiple myeloma.
| Characteristics | value |
|---|---|
| Sex, n (%) | 39 (47.0) |
| Male | 44 (53.0) |
| Female | |
| Age, median (range) years | 57 (42-75) |
| WBC, median (range) ×109/l | 4.9 (3.1-12.3) |
| Hb, median (range) g/l | 82 (60-103) |
| PLT, median (range) ×109/l | 193 (43-367) |
| Type, n (%) | |
| IgG | 55 (66.3) |
| IgA | 15 (18.1) |
| IgD | 3 (3.6) |
| Light chain | 8 (9.6) |
| NS | 2 (2.4) |
| D-S stage, n (%) | |
| I | 27 (32.5) |
| II | 24 (28.9) |
| III | 32 (38.6) |
| ISS stage, n (%) | |
| I | 37 (44.6) |
| II | 20 (24.1) |
| III | 26 (31.3) |
| R-ISS stage, n (%) | |
| I | 35 (42.2) |
| II | 23 (27.7) |
| III | 25 (30.1) |
| mSMART risk status, n (%) | |
| Low | 46 (55.4) |
| Intermediate | 21 (25.3) |
| High | 16 (19.3) |
| Percentage of MM cells in | 37 (14-73) |
| bone marrow, median (range) | |
| Bence-Jone protein, n (%) | 59 (71.1) |
| ESR elevated | 63 (75.9) |
| LDH elevated | 41 (49.4) |
| Hypercalcemia, n (%) | 9 (10.8) |
| Renal failurea, n (%) | 27 (32.5) |
| Bone lesions | 42 (50.6) |
a
Serum creatinine ≥2 mg/100 ml. NS, non-secretory; D-S, Durie-Salmon; ISS, International Staging System; R-ISS, Revised International Staging System; ESR, erythrocyte sedimentation; LDH, lactate dehydrogenase; mSMART, Mayo Stratification of Myeloma and Risk-Adapted Therapy.